Shareholder alert: Securities fraud class action announced by Bernstein Liebhard LLP.

A recent announcement by Bernstein Liebhard LLP has brought to light a securities fraud class action lawsuit that has been filed against Vistagen Therapeutics, Inc. The lawsuit was filed on behalf of investors who purchased or acquired the common stock of Vistagen between April 1, 2024, and December 16, 2025.

If you have owned shares of Vistagen Therapeutics, Inc. during the specified period and have experienced losses, you may be eligible to join the class action lawsuit. The lawsuit alleges that the company made misleading statements regarding the Phase 3 PALISADE-3 trial study of fasedienol, an investigational candidate for the treatment of social anxiety disorder.

Bernstein Liebhard LLP, the law firm responsible for the lawsuit, has a history of recovering billions of dollars for its clients since 1993. The firm represents individual investors and works with some of the largest public and private pension funds in the country to protect their assets and pursue legal action on their behalf. With a track record of success in litigating hundreds of class actions, Bernstein Liebhard LLP has garnered recognition in The National Law Journal’s “Plaintiffs’ Hot List” multiple times and has been consistently listed in The Legal 500 for sixteen years.

For those interested in participating in the class action lawsuit against Vistagen Therapeutics, Inc., it is essential to take action by the specified deadline to potentially benefit from any recovery. While it is encouraged to consider becoming a lead plaintiff for the class, taking no action will still allow you to be an absent class member. It is important to note that all legal representation in this matter is provided on a contingency fee basis, meaning shareholders are not responsible for any fees or expenses.

In conclusion, the securities fraud class action lawsuit filed against Vistagen Therapeutics, Inc. serves as an opportunity for affected investors to seek potential recovery for their losses. The allegations of misleading statements made by the company regarding the Phase 3 trial study highlight the importance of holding corporations accountable for their actions to protect the interests of shareholders and investors. If you believe you have been impacted by the alleged misconduct, it is advisable to explore your legal options within the specified timeframe to potentially recoup any losses suffered during the relevant period.